MUTYH is a potential prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma

被引:3
|
作者
Yang, Fan [1 ,2 ,3 ]
Lian, Qinghai [4 ]
Ni, Beibei [4 ]
Qiu, Xiusheng [4 ]
He, Yizhan [1 ]
Zou, Xiaoguang [2 ]
He, Fangping [5 ]
Chen, Wenjie [1 ,4 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Biotherapy Ctr, Guangzhou, Guangdong, Peoples R China
[2] First Peoples Hosp Kashi, Dept Infect Dis, Kashi, Xinjiang, Peoples R China
[3] Xinjiang Med Univ, Urumqi, Xinjiang, Peoples R China
[4] Sun Yat Sen Univ, Ailiated Hosp 3, Cell Gene Therapy Translat Med Res Ctr, Guangzhou, Guangdong, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Hepatobiliary & Pancreat Surg, Shenzhen, Guangdong, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
MUTYH; Hepatocellular carcinoma (HCC); Bioinformatics; Prognostic biomarker; Immune infiltrates; DNA-REPLICATION; CANCER; SURVEILLANCE; CHECKPOINTS; HOMOLOG;
D O I
10.1016/j.livres.2022.12.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. The development of biomarkers for early detection and monitoring of HCC has not shown significant prog-ress. Meanwhile, the second adenomatous polyposis-related gene, MUTYH, which encodes a DNA gly-cosylase, has been observed in its contribution to oxidative DNA damage repair. Abnormal expression of MUTYH can reduce cell survival rate. Therefore, this study investigated the usefulness of MUTYH in diagnosing and prognosis HCC.Materials and methods: Using The Cancer Genome Atlas (TCGA) data, we analyzed the prognostic value of MUTYH in HCC. We used logistic regression, Wilcoxon signed-rank test, and Kruskal-Wallis test to examine MUTYH expression concerning clinical-pathologic characteristics. Univariate and multivariate Cox regression methods and Kaplan-Meier analysis were applied to determine the related prognostic factors of HCC. The enrichment analysis (GSEA) was used to determine the critical pathways associated with MUTYH. The single-sample gene set enrichment analysis (ssGSEA) was conducted to examine the correlation between MUTYH expression and cancer immune infiltration.Results: The higher expression of MUTYH in HCC patients was associated with a poorer overall survival rate and a shorter disease-specific survival rate. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that all differentially expressed genes (DEGs) between the high and low expression levels of MUTYH significantly enriched in the trace ligand-receptor interaction, cell cycle, oocyte meiosis, gap junction, and DNA replication. Group analysis revealed the signals of their open access. The neuron system, M phase, DNA repair, Rho GTPase effector, and cell cycle checkpoints were significantly enriched. ssGSEA showed a positive correlation between MUTYH expression and the infiltration levels of Th2 cells, NK cells, and T helper cells. Moreover, a negative correlation was found between MUTYH expression and the infiltration levels of dendritic cells (DCs) and cytotoxic cells.Conclusions: MUTYH expression levels were positively correlated with immune checkpoint gene expression levels in HCC tissues. The expression level of MUTYH was related to the prognosis of HCC and the immune infiltration of HCC.& COPY; 2022 The Third Affiliated Hospital of Sun Yat-sen University. Publishing services by Elsevier B. V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:258 / 268
页数:11
相关论文
共 50 条
  • [1] CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
    Gu, Yurong
    Li, Xiangyong
    Bi, Yanhua
    Zheng, Yubao
    Wang, Jialiang
    Li, Xiaoyan
    Huang, Zexuan
    Chen, Lubiao
    Huang, Yanlin
    Huang, Yuehua
    AGING-US, 2020, 12 (01): : 784 - 807
  • [2] ATP13A2 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma
    Jinlan Huang
    Siyi Xu
    Zhou Yu
    Yansong Zheng
    Bin Yang
    Qishui Ou
    Journal of Gastrointestinal Surgery, 2023, 27 : 56 - 66
  • [3] ATP13A2 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma
    Huang, Jinlan
    Xu, Siyi
    Yu, Zhou
    Zheng, Yansong
    Yang, Bin
    Ou, Qishui
    JOURNAL OF GASTROINTESTINAL SURGERY, 2023, 27 (01) : 56 - 66
  • [4] MRGBP is a potential novel prognostic biomarker and is correlated with immune infiltrates in hepatocellular carcinoma
    Huang, Juanjun
    Chen, Xiaoli
    Zhu, Wei
    MEDICINE, 2021, 100 (12) : E25234
  • [5] Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma
    Wu, Min
    Jiang, Li
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (01) : 146 - 158
  • [6] Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma
    Min Wu
    Li Jiang
    Digestive Diseases and Sciences, 2022, 67 : 146 - 158
  • [7] Phosphatidylinositol glycan anchor biosynthesis, class C is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
    Zhao, Qian
    Shen, Chuan
    Wei, Junwei
    Zhao, Caiyan
    FRONTIERS IN GENETICS, 2022, 13
  • [8] APOE Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Papillary Thyroid Carcinoma
    Lin, Xu
    Zhang, Jing
    Zhao, Ru-Hua
    Zhang, Wen-Jing
    Wu, Jing-Fang
    Xue, Gang
    JOURNAL OF CANCER, 2022, 13 (05): : 1652 - 1663
  • [9] DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma
    Danjun Song
    Yining Wang
    Kai Zhu
    Lingyu Tian
    Qiang Gao
    Jian Zhou
    Jia Fan
    Xiaoying Wang
    World Journal of Surgical Oncology, 18
  • [10] DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma
    Song, Danjun
    Wang, Yining
    Zhu, Kai
    Tian, Lingyu
    Gao, Qiang
    Zhou, Jian
    Fan, Jia
    Wang, Xiaoying
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)